Premium
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
Author(s) -
Hiddemann W.,
Barbui A.M.,
Canales Albendea M.A.,
Cannell P.K.,
Collins G.P.,
Dürig J.,
Forstpointner R.,
Herold M.,
Hertzberg M.,
Klanova M.,
Radford J.A.,
Tobinai K.,
Burciu A.,
FingerleRowson G.R.,
Nielsen T.,
Wolbers M.,
Marcus R.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_106
Subject(s) - obinutuzumab , medicine , rituximab , follicular lymphoma , regimen , bendamustine , chemotherapy , chemotherapy regimen , febrile neutropenia , neutropenia , chop , surgery , gastroenterology , lymphoma , oncology